Related Experiment Video
Updated: Jun 25, 2025
09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
355
Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy
Jisan Hong1, Dahye Sim1, Byung-Heon Lee1
1Department of Biochemistry and Cell Biology, Cell & Matrix Research Institute, Kyungpook National University, School of Medicine, Daegu, 41944, Republic of Korea.
Journal of Nanobiotechnology
|May 27, 2024
Summary
Tat-A86 nanoparticles effectively deliver miRNA-34a to inhibit tumor growth. This novel system enhances miRNA stability and tumor cell uptake, overcoming key delivery challenges for improved cancer treatment efficacy.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapeutics
Background:
- Exogenous microRNA (miRNA) delivery shows promise for cancer treatment but faces challenges like short half-life and off-target effects.
- Current miRNA delivery methods are often inefficient, costly, and susceptible to degradation.
- Developing stable and targeted miRNA delivery systems is crucial for effective cancer therapy.
Purpose of the Study:
- To develop and evaluate Tat-A86 nanoparticles for enhanced delivery of miRNA-34a.
- To overcome limitations of conventional miRNA delivery, including stability and tumor targeting.
- To assess the therapeutic efficacy of miRNA-34a delivered by Tat-A86 in preclinical cancer models.
Main Methods:
- Genetically engineered Tat-A86 nanoparticles were constructed using an elastin-like polypeptide (ELP) for stability and targeting.
- Tat-A86 nanoparticles were loaded with miRNA to form stable nanocomplexes.
- In vitro studies used 3D spheroids of Lewis lung carcinoma (LLC), and in vivo studies used LLC tumor-bearing mice.
- Comparative groups (Tat-E60, A86) were used to assess binding and penetration efficacy.
Main Results:
- Tat-A86 nanoparticles successfully condensed miRNA, forming stable nanocomplexes under physiological conditions.
- miRNA/Tat-A86 formulation demonstrated specific binding to tumor cells and efficient intracellular delivery.
- Significant inhibition of tumor growth was observed in both 3D spheroid and in vivo mouse models.
- Tat-A86 showed superior efficacy in reducing tumor size and suppressing tumor cell growth compared to control groups.
Conclusions:
- Tat-A86 nanoparticles provide a stable and effective system for systemic miRNA delivery.
- This delivery platform overcomes major hurdles in miRNA delivery, enhancing cellular uptake and stability.
- The results indicate improved therapeutic effects, highlighting the potential of Tat-A86 for miRNA-based cancer therapy.
